Hepatocellular carcinoma (HCC) is an aggressive tumor that often arises in the
setting of liver cirrhosis. Although early-stage disease is often amenable for
surgical resection, transplant, or locoregional therapies, many patients are
diagnosed at an advanced stage or have poor liver reserve. Systemic therapy is
the mainstay of treatment for these patients. At present, the only approved
therapy for the treatment of advanced disease is the tyrosine multikinase
inhibitor sorafenib. Candidacy for treatment is based on liver reserve. Novel
agents for the treatment of this disease are urgently needed. In this article,
we review systemic therapy trials and upcoming data for the treatment of
HCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.